Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 06, 2022

Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Clin. Cancer Res 2022 Aug 15;28(16)3433-3442, M Cristofanilli, HS Rugo, SA Im, DJ Slamon, N Harbeck, I Bondarenko, N Masuda, M Colleoni, A DeMichele, S Loi, H Iwata, B O'Leary, F André, S Loibl, E Bananis, Y Liu, X Huang, S Kim, MJ Lechuga Frean, NC Turner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading